CN1039588C - 新的抗肿瘤铂络合物 - Google Patents

新的抗肿瘤铂络合物 Download PDF

Info

Publication number
CN1039588C
CN1039588C CN95103058A CN95103058A CN1039588C CN 1039588 C CN1039588 C CN 1039588C CN 95103058 A CN95103058 A CN 95103058A CN 95103058 A CN95103058 A CN 95103058A CN 1039588 C CN1039588 C CN 1039588C
Authority
CN
China
Prior art keywords
platinum
platinum complex
complex compound
cis
antineoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95103058A
Other languages
English (en)
Other versions
CN1120544A (zh
Inventor
邹娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dou Peiyan
Original Assignee
Dou Peiyan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dou Peiyan filed Critical Dou Peiyan
Priority to CN95103058A priority Critical patent/CN1039588C/zh
Publication of CN1120544A publication Critical patent/CN1120544A/zh
Application granted granted Critical
Publication of CN1039588C publication Critical patent/CN1039588C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

一种新的抗肿瘤顺铂络合物类似物,其结构为CisPtAX,其中携带基团A为二氨基或环已二胺基,离去基团X为去甲基斑螯酸根或硒酸根。这类铂络合物类似物的毒性小,抗肿瘤效果比目前已知的顺铂络合物都好,其合成工艺易便可靠。

Description

新的抗肿瘤铂络合物
本发明涉及一种抗肿瘤的铂络合物,特别涉及以去甲基斑螯酸根或硒酸根为配体的抗肿瘤铂络合物。
最近几十余年来发现顺铂具有抗肿瘤的作用后,开辟了一个抗肿瘤药物研究的新领域,已筛选了数以万计的CisPtAX顺铂类似物,研究者往往是变换顺铂类似物中携带基团A和离去基团X,以开发出活性高,稳定性和溶解性更好的络合物。从临床上看,以氨、环己二胺或邻苯二胺为配体A的顺铂络合物具有较好活性和较低的毒性,已为人们所接受。故目前的广大研究者是从配体X着手,寻求抗肿瘤更有效的顺铂类似物,例如:us-4562275公开了
Figure C9510305800031
的抗肿瘤铂络合物。但从这些顺铂络合物的离去基团
Figure C9510305800033
来看,还没有见过锰和络酸根能抗肿瘤的报导,再如us-5128.493所公开的X基团是 的新合成顺铂类似物及us-5,298,642所公开的X基团为 的顺铂类似物,但都没有提到抗肿瘤的报导
本发明的目的在于提供一种X基团具有防止肿瘤和新的X基团的顺铂类似物,其毒性比现有的顺铂络合物低,其活性则有明显提高的新的抗肿瘤铂络合物。
本发明的实施方案如下:
以二氨或环己二胺作为携带基团(A)的铂络合物,和以去甲基斑螯酸根或硒酸根为离去基团X的新型抗肿瘤顺铂类似物,其结构为CisPtAX,其中A为二氨或环己二胺,X为去甲基斑螯酸根或硒酸根,具体络合物如下:
(1)环己二胺去甲基斑螯酸根合铂(II)
Figure C9510305800041
(2)环己二胺硒酸根合铂(II)
Figure C9510305800042
(3)二氨硒酸根合铂(II)
Figure C9510305800043
现叙述其合成方法:络合物(1)的合成:按现有技术从K2PtCl4制备K2PtI4再制备成
Figure C9510305800044
另外按现有技术方法从
然后将(1’)(1”)反应成
Figure C9510305800052
其反应式如下:
Figure C9510305800053
络合物(2)的合成:
按现有技术将 在水中与AgNO3反应生成
Figure C9510305800055
然后再将(2’)络合物与硒酸钠反应生成
Figure C9510305800056
其反应式如下:
Figure C9510305800057
络合物(3)的合成:
按现有技术用K2PtCi4制备K2PtI4再制成
Figure C9510305800058
最后制成
Figure C9510305800059
然后将(3’)络合物与硒酸钠反应而成本发明的产物
Figure C95103058000510
其反应式如下:
下面的优选例对本发明作详细说明,但不意味着限制本发明的范围。
例1:环己二胺去甲基斑螫酸根合铂
Figure C9510305800061
的合成
准确称取0.137克去甲基斑螯酸银和0.193克二碘环己二胺合铂,放入一个25毫升的三角瓶中用10毫升水将其调成糊状,再加入5毫升水,在避光下搅拌12小时,滤去碘化银沉淀物,得到澄清母液。浓缩母液,静置析出白色粉末状固体,抽滤,用无水乙醇.无水乙醚冲洗三次,于室温下干燥,得白色粉末52.9毫克的本发明产物环己二胺去甲基斑螫酸根合铂(II)。
经红外光谱分析:环己二胺出现
Figure C9510305800062
在3261和3310cm-1络合物氨基伸缩振动峰
Figure C9510305800063
出现在3187和3142cm-1,该络合物氨基的弯曲振动峰δPt-N出现在1604cm-1(S),原羧基的特征吸收峰V-C=O与V-COO-分别出现在1639cm-1(S)和1389cm-1(S),
均在指纹区(806cm-1,581cm-1,407cm-1),在水中的导电率为15.47Ω-1·cm-1·ml-1。即非电解质。
其急性毒性及抗肿瘤效果见表1和表2。
例2:环己二胺硒酸根合铂(II) 的合成在一个25毫升的三角瓶中加入15毫升(含有0.355摩尔)
Figure C9510305800065
      水溶液中加入含10个结晶水的硒酸钠0.131克,于室温下反应5小时,在50℃下浓缩母液,得0.14克的本发明产物(2)
经红外光谱分析:氨基伸缩振动位于3215和3095cm-1,弯曲振动位于1581cm-1(br),VPt-N 442cm-1(W),硒酸钠的吸收峰位于879cm-1(S,br),414cm-1(S),与铂配位后峰位为883cm-1(S),792cm-1,616cm-1,544cm-1
在水中的导电率为184.8Ω-1·cm-1·mol-1,有部分发生电离。
其急性毒性和抗肿瘤效果见表1和表2
例3:二氨硒酸根合铂(II)
Figure C9510305800072
的合成在一个25毫升的三角瓶中,加入15毫升(含有0.414摩尔)
Figure C9510305800073
水溶液中,加入含10个结晶水的硒酸钠0.153克,于室温下反应5小时,在50℃下浓缩母液,得61.6毫克的本发明产物(3)
经红外光谱分析:
Figure C9510305800075
3280cm-1,3138cm-1
Figure C9510305800076
1587cm-1,5561cm-1,VPt-N 542cm-1,硒酸钠的吸收峰位于879cm-1,414cm-1,与铂配位后峰位为885cm-1,843cm-1,792cm-1,在水中导电率为1054.1Ω·cm-1·mol-1,为电解质。
其急性毒性与抗肿瘤效果见表1和表2。
急性毒性:用体重为20±2g的昆明种小鼠,雌雄各半,从尾静脉一次给药,设五个剂量,每个剂量10只小鼠,观察7天其死亡及精神状况,计算出LD50
               表1    急性毒性
    络合物(1)       络合物(2)      络合物(3)     顺铂对照LD50   >26mg/kg       >20mg/kg                    13mg/kg
                     表2  体外抗肿瘤试验IC50(μM)
        人肝癌    人结肠癌   人鼻咽癌  人胃癌     人白血       人红白血病
         Bel-740  HCI瘤株    KB瘤株    BGC瘤株    病HL-60      K562瘤株
         瘤株                                     瘤株络合物(1)    5.9       1.7        1.6       2.2        8.4          2.2络合物(2)    1.9       1.3        1.4       0.3        0.4          0.3络合物(3)    无效      9.0        3.1       0.68       无效         无效顺铂对照     7.7       3.9        1.3       0.68                    2.7
本发明的三个顺铂络合物的优点是:
1.毒性小,抗肿瘤效果好,
2.合成工艺易便,可靠,
3.络合物稳定性好,不易水解。

Claims (4)

1.一种新的抗肿瘤顺铂络合物类似物,其特征在于其结构式为:
    CisAPtX
其中A为二氨基或环己二胺基即
Figure C9510305800022
    X为去甲基斑螯酸根或硒酸根,即
Figure C9510305800023
Figure C9510305800024
2.根据权利要求1的抗肿瘤顺铂络合物类似物,其特征在于所述A配体为环己二胺基,所述X配体为去甲基斑螯酸根,即
Figure C9510305800025
3.根据权利要求1的抗肿瘤顺铂络合物类似物,其特征在于所述A为环己二胺基,X为硒酸根,即
Figure C9510305800026
4.根据权利要求1的抗肿瘤顺铂络合物类似物,其特征在于所述A为二氨基,X为硒酸根,即
CN95103058A 1995-03-29 1995-03-29 新的抗肿瘤铂络合物 Expired - Fee Related CN1039588C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN95103058A CN1039588C (zh) 1995-03-29 1995-03-29 新的抗肿瘤铂络合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95103058A CN1039588C (zh) 1995-03-29 1995-03-29 新的抗肿瘤铂络合物

Publications (2)

Publication Number Publication Date
CN1120544A CN1120544A (zh) 1996-04-17
CN1039588C true CN1039588C (zh) 1998-08-26

Family

ID=5074585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95103058A Expired - Fee Related CN1039588C (zh) 1995-03-29 1995-03-29 新的抗肿瘤铂络合物

Country Status (1)

Country Link
CN (1) CN1039588C (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043623A1 (fr) * 2001-11-23 2003-05-30 Wei Wang Compositions pharmaceutiques antivirales, antibacteriennes d'anhydride cantharidique et son procede de preparation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
CN100344293C (zh) * 2000-09-26 2007-10-24 株式会社东京大学Tlo 包封顺铂的高分子微胶粒及其用途
SI1695991T1 (sl) * 2003-12-10 2010-04-30 Toudai Tlo Ltd Koordinacijski kompleks diaminocikloheksan platine (II) z blok kopolimerom, ki vsebuje segment poli(karboksilne kisline) in antitumorni agens, ki jih vsebuje
CN1680384A (zh) * 2004-04-08 2005-10-12 香港中文大学 去甲基斑蟊素铂配合物及其用途
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
CN101967163B (zh) * 2010-09-07 2012-07-25 昆明贵金属研究所 对癌细胞有选择性的铂(ⅱ)抗癌配合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562275A (en) * 1984-03-23 1985-12-31 Bristol-Myers Co. Antitumor platinum complexes
US5128493A (en) * 1987-02-19 1992-07-07 Nippon Kayaku Kabushiki Kaisha Platinum complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562275A (en) * 1984-03-23 1985-12-31 Bristol-Myers Co. Antitumor platinum complexes
US5128493A (en) * 1987-02-19 1992-07-07 Nippon Kayaku Kabushiki Kaisha Platinum complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043623A1 (fr) * 2001-11-23 2003-05-30 Wei Wang Compositions pharmaceutiques antivirales, antibacteriennes d'anhydride cantharidique et son procede de preparation

Also Published As

Publication number Publication date
CN1120544A (zh) 1996-04-17

Similar Documents

Publication Publication Date Title
US10150792B2 (en) Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
RU2335512C2 (ru) Координационный комплекс диаминоциклогексана платины (ii) с блоксополимером, содержащим сегмент поли(карбоновой кислоты), и включающий его противораковый агент
CN111171080B (zh) 细胞及活体内自催化合成的高效低毒抗癌化合物及其合成方法
CA1259325A (en) Oral compositions
EP0395441B1 (en) Treating agent for osteoarthritis
CN1039588C (zh) 新的抗肿瘤铂络合物
WO1982000145A1 (en) Platinum(ii)complexes and antineoplastic agents containing same as effective ingredients
KR100442096B1 (ko) 이중 디카르복실산 디아미노플라틴 착체의 항종양 유도체, 그의 제조방법, 그것을 함유하는 약학조성물 및 그 유도체의 적용
GB2077720A (en) Organic complex of platinum
Avaji et al. Synthesis and properties of a new micellar polyphosphazene–platinum (II) conjugate drug
JP3715650B2 (ja) 新規白金(iv)錯体、その製造方法及びそれを含む制癌剤
US4687780A (en) Anti-tumor compounds of platinum
Wang et al. Potential new antitumor agents from an innovative combination of camphorato, a ramification of traditional Chinese medicine, with a platinum moiety
JPS61500909A (ja) 混合カルボキシラト白金(2)錯体類およびその製法
CN108409781B (zh) 一种六钒酸-l-丙氨酸叔丁酯衍生物及其制备方法与应用
CN101328224B (zh) 广枣多糖金属配合物及其制取方法
RU2635562C2 (ru) Новые соединения бензолполикарбоновых кислот
JP2015520121A5 (zh)
Hao et al. Preparation, chemical characterization and determination of the antioxidant, cytotoxicity and therapeutic effects of gold nanoparticles green-synthesized by Calendula officinalis flower extract in diabetes-induced cardiac dysfunction in rat
CN114591511A (zh) 一种模拟天然超氧化物歧化酶的铜基配位聚合物及其制备方法和应用
US4211712A (en) Complex compound for the treatment of diseases disclosing abnormal blood pictures
JP6887195B1 (ja) 新規有機ゲルマニウム化合物
CN1274674C (zh) 丙二硒桥联双环糊精铂配合物的用途
KR100258735B1 (ko) 키토산 유기 게르마늄 화합물의 제조방법
FI62283C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-2'-karboxifenyl-4-klorantranilsyraderivat

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee